Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.gov public full text Public Domain

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Sichuan Cancer Hospital and Research Institute · 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
cervical-cancerendometrial-cancergynecologic-cancerovarian-cancer
To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignancies, yet chemotherapy-induced nausea and vomiting (CINV) remain common and distressing. Optimal prophylaxis is uncertain. This trial evaluated whether adding the NK1 receptor antagonist aprepitant to standard two-drug prophylaxis (5-HT3 receptor antagonist plus dexamethasone) improves CINV control.
Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 805631
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive